482 related articles for article (PubMed ID: 33400393)
21. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
Noroozi Tiyoula F; Aryapour H
PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
[TBL] [Abstract][Full Text] [Related]
22. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.
Zhu J; Zhang H; Lin Q; Lyu J; Lu L; Chen H; Zhang X; Zhang Y; Chen K
Drug Des Devel Ther; 2022; 16():1067-1082. PubMed ID: 35450403
[TBL] [Abstract][Full Text] [Related]
23. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
26. Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.
Sharma A; Kaliya K; Maurya SK
Curr Top Med Chem; 2021; 21(4):307-328. PubMed ID: 33183205
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
28. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
Vandyck K; Deval J
Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
[TBL] [Abstract][Full Text] [Related]
29. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
Capasso C; Nocentini A; Supuran CT
Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
[TBL] [Abstract][Full Text] [Related]
31. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
32. Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.
Ferreira JC; Fadl S; Ilter M; Pekel H; Rezgui R; Sensoy O; Rabeh WM
FASEB J; 2021 Aug; 35(8):e21774. PubMed ID: 34324734
[TBL] [Abstract][Full Text] [Related]
33. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
Rothan HA; Teoh TC
Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
[TBL] [Abstract][Full Text] [Related]
34. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.
O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC
Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599
[TBL] [Abstract][Full Text] [Related]
35. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease.
Sur VP; Sen MK; Komrskova K
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684780
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
Tatar G; Salmanli M; Dogru Y; Tuzuner T
J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
[TBL] [Abstract][Full Text] [Related]
37. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Cannalire R; Cerchia C; Beccari AR; Di Leva FS; Summa V
J Med Chem; 2022 Feb; 65(4):2716-2746. PubMed ID: 33186044
[TBL] [Abstract][Full Text] [Related]
38. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues.
Xu L; Tong J; Wu Y; Zhao S; Lin BL
Biophys Chem; 2021 Sep; 276():106610. PubMed ID: 34089978
[TBL] [Abstract][Full Text] [Related]
39. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
[TBL] [Abstract][Full Text] [Related]
40. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
Yassine R; Makrem M; Farhat F
Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
